Sensei biotherapeutics provides corporate update and highlights key upcoming milestones

- solnerstotug (sns-101) dose expansion arm anticipated to be fully enrolled by end of q1 2025 - - clinical data update expected in q2 2025 - boston, jan. 08, 2025 (globe newswire) -- sensei biotherapeutics, inc. (nasdaq: snse), a clinical stage biotechnology company focused on the discovery and development of next-generation therapeutics for cancer patients, today provided corporate updates on its lead program, solnerstotug (sns-101) and upcoming milestones. “2024 was a noteworthy year for sensei and our pioneering lead program, solnerstotug.
SNSE Ratings Summary
SNSE Quant Ranking